MedTrace Logo

Efficacy and Safety of Daptomycin Versus Vancomycin or Teicoplanin for Treatment of Complicated Skin and Soft Tissue Infections

NCT00430937 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 194

Last updated 2012-07-16

Study results available
· View outcomes & findings →

Summary

This study evaluated the efficacy and safety of daptomycin compared to vancomycin or teicoplanin for the treatment of complicated skin and soft tissue infections

Conditions

  • Skin Diseases, Infectious
  • Soft Tissue Infections

Interventions

DRUG

Daptomycin

4 mg/kg intravenous once daily

DRUG

Vancomycin

1 g intravenous twice daily

DRUG

Teicoplanin

400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2008-03-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00430937 on ClinicalTrials.gov